Dr. Reddys Laboratories Ltd along with its subsidiaries announced the launch of fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg extended-release tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D 12 HR allergy and congestion extended-release tablets, in the United States market, as approved by the US Food and Drug Administration (FDA).
Dr. Reddy's Laboratories Ltd announced the launch of the US Food and Drug Administration (FDA) approved trientine hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) capsules. Dr Reddy's trientine hydrochloride capsules USP, 250 mg are available in 100 count bottles. "We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners," explains Marc Kikuchi, chief executive officer and head of Dr. Reddy's North America Generics. "Our product can be stored at room temperature (20°C to 25°C or 68° F to 77°F) throughout the product shelf life of 24 months." The Syprine brand and generic products had US sales or approximately US$ 94.2 million MAT for the most recent twelve months ending in December 2019, according toIQVIA.
Dr Reddy's Laboratories Ltd announced the launch of a generic version of sapropterin dihydrochloride tablets, for oral use.
"We are pleased to launch this generic version of sapropterin dihydrochloride tablets, for oral use, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, chief executive officer, North America Generics, Dr Reddy's Laboratories.
"At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease. We are pleased to provide financial support to patients by offering a co-pay card program for eligible patients, details will be available on our website," added Kikuchi.
Dr Reddy's sapropterin dihydrochloride tablets, 100 mg are available in bottle count sizes of 120.
Dr Reddy's Laboratories Ltd announced the launch of febuxostat tablets, a therapeutic equivalent generic version of Uloric (febuxostat) tablets approved by the US Food and Drug Administration (FDA).
The Uloric brand and generic had US sales of approximately US$ 108 million MAT for the most recent twelve months ending in October 2020, according to IQVIA Health.
Dr Reddy's febuxostat tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets
